Summary
We have studied the effects of 12 weeks of lovastatin (20 mg per day) on platelet function and thromboxane formation in 18 patients with type II hypercholesterolaemia in a double-blind, placebo-controlled, prospective study.
Lovastatin significantly reduced total serum and LDL-cholesterol by 20% and 25% respectively. Washed platelets of lovastatin-treated patients had significantly reduced collagen-induced aggregation and thromboxane formation ex vivo. There was no change in ADP-induced platelet aggregation, but a significant increase in prostacyclin (iloprost)-stimulated platelet cyclic AMP concentrations in lovastatin-treated patients. This was associated with a significant increase in the number of prostacyclin receptors in platelet membranes prepared from lovastatin-treated patients. There was also an increase in platelet thromboxane receptors. There were no such changes in the placebo group.
These data confirm our original observation of normalization of platelet function in hypercholesterolaemia by HMGCoA reductase inhibitors and suggest changes in platelet membrane composition at the megakaryocyte level as a possible site of action.
Similar content being viewed by others
References
Aviram M (1989) Modified forms of low density lipoprotein affect aggregation in vitro. Thromb Res 53: 561–567
Barrow SE, Stratton PD, Benjamin N, Brassfield T, Ritter JM (1991) Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolemia at risk of coronary heart disease. Br J Clin Pharmacol 32: 127–129
Bruckdorfer KR, Buckley S, Hassall DG (1984) The effect of LDL on the synthesis of cyclic nucleotides induced by prostacyclin in isolated platelets. Biochem J 223: 189–196
Carvalho ACA, Colman RW, Lees RS (1974) Platelet function in hyperlipoproteinemia. New Engl J Med 290: 434–438
Colli S, Lombroso M, Maderna P, Tremoli E, Nicosia S (1983) Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia. Biochem Pharmacol 32: 1989–1993
Colli S, Maderna P, Tremoli E, Baraldi A, Rovati GE, Gianfranceschi G, Nicosia S (1985) Prostacyclin-lipoprotein interactions. Studies on human platelet aggregation and adenylate cyclase. Biochem Pharmacol 34: 2451–2457
Colli DW, Maderna P, Accomazzo MR, Nicosia S, Tremoli E (1989) Iloprost binding and inhibition of aggregation in platelet rich plasma. Differences between normal and type IIa hypercholesterolemic subjects. Biochem Pharmacol 38: 39–45
Davi G, Maderna M, Novo S, Barbagallo CM, Mogavero A, Notarbartolo A, Strano A (1989) Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients. Atherosclerosis 79: 79–83
Di Minno G, Cerbone AM, Cirillo F, Postiglione A, Colucci M, Semeraro N, Scarpato N, Gnasso A, Margaglione M, Galotta G (1990) Hemostatic variables in homozygous familial hypercholesterolemia. Effect of regular plasma cholesterol removal by low density lipoprotein apheresis. Arteriosclerosis 10: 1119–1126
Eynard AR, Tremoli E, Caruso D, Magni F, Sirtori CR, Galli C (1986) Platelet formation of 12-hydroxyeicosatetraenoic acid and thromboxane B2 is increased in type IIa hypercholesterolemic subjects. Atherosclerosis 60: 61–66
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499–502
Gotto AM (Chairman) (1989) American Heart Association Conference report on cholesterol. Circulation 80: 717–748
Jakubowski JA, Ardlie NG, Nestel PJ (1980) The effect of hypercholesterolaemia on the lipid composition and ability of human platelets to accumulate cyclic AMP. Prostaglandins Med 5: 457–467
Jaschonek K, Funk M, Muller CP (1989) Modulation of platelet [3H] iloprost binding by cholesterol, dibucaine and pentoxifylline. In: Schrör K, Sinzinger H (eds) Prostaglandins in Clinical Research. Liss, New York, pp 321–325
Kramer RM, Jakubowski JA, Vaillancourt R, Deykin D (1982) Effect of membrane cholesterol on phospholipid metabolism in thrombin-stimulated platelets. J Biol Chem 257: 6844–6849
L'Abbate R, Modesti PA, Fortini A, Lombardi A, Matucci M, Gensini GF, Neri Serneri GG, Fellin R, Valerio G, Crepaldi G (1985) Decreased number of PGD2 binding sites on platelets from patients with type IIa hyperlipoproteinemia. Atherosclerosis 54: 167–175
Löbel P, Steinhagen-Thiessen E, Schrör K (1988) Cholestyramine treatment of type IIa hypercholesterolemia normalizes platelet reactivity against prostacyclin. Eur J Clin Invest 18: 256–260
Malle E, Sattler W, Prenner E, Leis HJ, Karàdi I, Knipping G, Romics L, Kostner GM (1991) Platelet membrane fluidity in type IIA, type IIB, and type IV hyperlipoproteinemia. Atherosclerosis 87: 159–167
Martin JF, Slater DN, Kishk YT, Trowbridge EA (1985) Platelet and megakaryocyte changes in cholesterol induced experimental atherosclerosis. Arteriosclerosis 5: 604–612
Mosconi C, Colli S, Tremoli E, Galli C (1988) Phosphatidylinositole (PI) and PI-associated arachidonate are elevated in platelet total membranes from type IIa hypercholesterolemic subjects. Atherosclerosis 72: 129–134
Neaton JD, Wentworth D (1992) Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch Int Med 152: 56–64
Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M (1985) Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 234: 435–441
Oliva DW, Maderna P, Accomazzo MR, Nicosia S, Tremoli E (1989) Iloprost binding and inhibition of aggregation in platelet rich plasma. Differences between normal and type IIa hypercholesterolemic subjects. Biochem Pharmacol 38: 39–45
Prisco D, Rogasi PG, Paniccia R, Coppo M, Abbate R, Gensini GF (1988) Altered lipid composition and thromboxane A2 formation in platelets from patients affected by IIa hyperlipoproteinemia. Thromb Res 50: 593–604
Schröder H, Strobach H, Schrör K (1992) Nitric oxide but not prostacyclin is an autocrine endothelial mediator. Biochem Pharmacol 43: 533–537
Schrör K (1990) Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinemia and its modification by cholesterol lowering agents. Eicosanoids 3: 67–73
Schrör K and Seidel H (1988) Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay. NS Arch Pharmacol 337: 177–186
Schrör K, Löbel P, Steinhagen-Thiessen E (1989) Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Eicosanoids 2: 39–46
Shattil SJ, Anaya-Galiudo R, Bennett J, Colman RW, Cooper RA (1975) Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 55: 636–643
Smith CM, Burris SM, Hunnighake DB, White JG (1988) Altered platelet deformability in patients with type IIa and type IV hyperlipoproteinemia. Am J Hematol 27: 247–252
Sorisky A, Kucera GL, Rittenhouse SE (1990) Stimulated cholesterol-enriched platelets display increased cytosolic Ca2+ and phospholipase A activity independent of changes in inositol triphosphates and agonist/receptor binding. Biochem J 265: 747–754
Strano A, Davi G, Averna M, Rini GB, Novo S, DiFede G, Mattina A, Notarbartolo A (1982) Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. Thromb Haemostasis 48: 18–20
Stuart MJ, Gerrard JM, White JG (1980) Effect of cholesterol on production of thromboxane B2 by platelets in vitro. New Engl J Med 302: 6–10
Tremoli E, Folco G, Agradi E, Galli C (1979) Platelet thromboxane and serum cholesterol. Lancet 1: 106–107
Tremoli E, Maderna P, Colli S, Morazzoni G, Sirtori M, Sirtori CR (1984) Increased platelet sensitivity and thromboxane B2 formation in type IIa hyperlipoproteinaemic patients. Eur J Clin Invest 14: 329–333
Warner P, Patscheke H (1980) Hyperreactivity by an enhancement of the arachidonate pathway of platelets treated with cholesterol-rich phospholipid dispersions. Thromb Res 18: 439–451
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaczmarek, D., Hohlfeld, T., Wambach, G. et al. The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. Eur J Clin Pharmacol 45, 451–457 (1993). https://doi.org/10.1007/BF00315517
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315517